FAKTOR OPTIONSSCHEIN - GILEAD SCIENCES | Real-time Bid/Ask 09:53:52 03/06/2024 BST | ||
| 10.8 EUR / 11.4 EUR | -0.09% |
|
| 1 month | +1.93% | ||
| 3 months | +34.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 10.82 | -2.61% |
| 31/05/24 | 11.11 | +0.18% |
| 30/05/24 | 11.09 | -3.31% |
| 29/05/24 | 11.47 | +2.59% |
| 28/05/24 | 11.18 | +9.50% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 08:39 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | UBS |
| WKN | UM10LJ |
| ISIN | DE000UM10LJ5 |
| Date issued | 26/02/2024 |
| Strike | 85.44 $ |
| Maturity | Unlimited |
| Parity | 1.75 : 1 |
| Emission price | 8.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.54 € |
|---|---|
| Lowest since issue | 6.86 € |
| Spread | 0.6 € |
| Spread % | 5.25% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.27
USD
Average target price
82.7
USD
Spread / Average Target
+28.67%
- Stock Market
- Certificates
- Certificat
